Updated Perspectives on the Management of Multiple Myeloma in Older Patients: Focus on Lenalidomide.

ABSTRACT: Multiple myeloma is a hematologic malignancy that predominantly affects older adults, with a median age at diagnosis of 70 years old. A mainstay of multiple myeloma treatment is lenalidomide, which is an immunomodulatory drug (IMiD) that changed the treatment paradigm for multiple myeloma. This is particularly true for older adults who do not undergo autologous stem cell transplantation (ASCT). Several pivotal trials summarized in this review demonstrate the efficacy and safety of lenalidomide in older adults with multiple myeloma, including significant improvements in response rates, progression-free survival and overall survival in the first-line and relapsed/refractory settings. Potential adverse effects include venous thromboembolism, cytopenias, and second malignancies and the doses t

SUBMITTER: Schoenbeck KL 

PROVIDER: S-EPMC7210019 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature